COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
Epicrispr is a South San Francisco biotech developing single‑AAV in vivo epigenetic therapies via its GEMS platform using ultracompact Cas DNA‑binding proteins (CasMINI), with lead program EPI‑321 for FSHD.
